Baseline characteristics of patients with very high risk of ASCVD
A total of 453 patients treated with PCSK-9 inhibitors combined with statin and 2,610 patients treated with statins were recruited in the cohort. Among all patients, 89.91% had received moderate or high-intensity statin therapy before PCI (eFigure 1A), but only 9.47% of them had LDL levels below 1.4mmol/L (eFigure 1B). The proportion of patients with Lp(a) level >430mmol/L was 44.85%.
PSM selected a subgroup of 868 patients (434 initiated treated with PCSK-9 and 434 treated with statins) were used for comparative effectiveness analysis in current study. The follow-up rate of 868 patients was 100% at 6 months. The patient flow chart was showed in eFigure 2.
The baseline characteristics of matched patients were summarized in Table 1. There was no statistical significant difference in age, gender, BMI, comorbidities, smoker and medical treatment after matched, but incidence of past history of MI, PCI, CABG, STEMI and ischemic cardiomyopathy in PSCK-9 inhibitor group is higher (all withP <0.001).